[MRNA]

Moderna surged 12% to reach a new high. Since the current stock price is above the resistance level, it is advisable to approach the stock after confirming the short-term support level. Take profit at 161.96 and cut losses at 130.0 — cut losses if the conditions are broken and take profit if the target is reached. Entry was considered under the judgment that, as the current stock price exceeds the previous 20-day resistance line, approaching the stock after confirming the short-term support line is valid. RSI (14) stands at 61.9, indicating moderate upward momentum just below the overbought zone, and moving averages maintain a bullish alignment. Trading volume is relatively subdued at 0.78 times the 20-day average, while the 7-day volatility/return rate records a strong upward momentum at +13.6%. At the time of the prediction, the stock price was already above the existing 20-day resistance line, leading to the view that an approach after confirming the short-term support line would be valid. However, the actual result significantly exceeded the projected return of 3.5%, recording a 17.5% return and receiving an OVERHIT rating. While upward momentum was captured based on the RSI (14) of 61.9, bull-aligned moving averages, and a +13.6% volatility rate over the past 7 days, this review highlights that an even steeper additional rally unfolded than expected, driven by the convergence of an increasing trend in biotech theme news and strong buying pressure. Since this trade confirmed the persistence of momentum in the phase above the resistance line, we will respond by flexibly allowing room for additional upside following a breakout above the short-term resistance line when an increase in news within the theme and bullish-aligned technical indicators occur simultaneously in the future.

CNBC's Jim Cramer noted that August was a month in which stocks previously hit by bearish narratives successfully rebounded. To state the conclusion first, I will take profit near the resistance level of 176.66, and cut losses if the 20-day moving average support line collapses or if the price breaks below the stop-loss level of 53.71. The current share price is moving stably above the 20-day moving average support line, and while there is upside potential toward the resistance level of 176.66, the volume trend must be closely monitored. To conclude, entry is recommended based on the stable stock price movement above the 20-day moving average support line and the upside potential toward the resistance level of 176.66. Over the past 7 days, candle data has shown an upward trend from the 150s to the 190s, and based on the RSI (14) of 68.2 and the bullish alignment of moving averages, a buy can be considered while confirming the rebound above the support line and the remaining upside potential. The technical indicators at the entry point are as follows: the RSI (14) stands at 68.2, and the moving averages are in a bullish alignment (stacked in ascending order). Trading volume is at 0.61 times the 20-day average, and the volatility over the past 7 days recorded +5.3%. To conclude, it recorded an actual return of 41.7%, significantly outperforming the projected return of 2.5%, and received an OVERHIT rating. While the initial direction was precisely correct—entering with expectations of upward potential based on stable support above the 20-day moving average, an RSI (14) of 68.2, and a bullish moving average alignment—it was a missed opportunity not to fully extrapolate the surging biotech theme news (which had increased to 66 articles over the past 7 days), the 11.9% S-Class conversion rate, and how much more powerfully the mRNA cancer vaccine late-stage clinical trial momentum, seen in past similar cases, would drive the stock price upward. To conclude, when strong theme momentum and core positive catalysts overlap, we will allow for additional upside potential beyond our conservative target price and incorporate this adaptability into our next trading decisions. Technically, we will enter the stock once 20-day moving average support and a positive moving average alignment are confirmed. If this coincides with overall positive sector sentiment—such as an increasing trend in theme-related news and S-Class conversion rates—we will execute a strategy with a slightly more flexible profit-taking benchmark. Past similar successful cases include three instances involving MRNA. The first is the case on 2026-09-13, which recorded a return of 128.7%, driven by overlapping keywords of 'Moderna' and expectations surrounding cancer vaccine results. The second is the case on 2026-08-20, which recorded a return of 125.8%, where overlapping keywords of 'Moderna' and late-stage melanoma clinical trial results impacted the stock price. The third is the case on 2026-08-28, which recorded a return of 113.7%, where overlapping keywords of 'Moderna' and news of late-stage clinical approval for an mRNA cancer treatment served as the momentum.

Regarding Moderna's cancer vaccine results, notable positive news is gaining traction across the biotech sector as a whole. As the trend continues and reaches the take-profit target of $176.66, I will take partial profits, and if the momentum breaks and falls below the stop-loss price of $52.66, I will execute an immediate stop-loss. Amid favorable news regarding Moderna's cancer vaccine, and given that the moving averages are in a bullish alignment as of the entry point, volume has surged 4.38-fold compared to the 20-day average, and strong upward momentum is forming with a 7-day volatility rate reaching +127.9%, a purchase may be considered. Looking at the technical indicators at the entry point, the RSI (14) is at 74.7, entering the overbought zone, the moving averages are in a bullish alignment, trading volume is 4.38 times the 20-day average, and the volatility over the past 7 days recorded +127.9%. An unexpectedly steep upward trend unfolded, resulting in an actual return of 11.6%, which significantly outperformed the projected return (3.5%) and received an OVERHIT rating. Given that the RSI (14) was at 74.7 in the overbought zone at the time of entry, trading volume surged 4.38-fold compared to the 20-day average, and the 7-day volatility reached +127.9%, this serves as a reminder that we approached the situation rather conservatively by failing to fully reflect the additional upward momentum driven by strong supply and demand inflows in our projections. As confirmed in this trade, in a phase where trading volume surges more than 4 times the 20-day average, the number of news items within the theme increases, and the S-Class conversion rate is supported, we will actively reflect strategic flexibility in future trades by flexibly raising the take-profit target price or holding proportion, trusting the persistence of momentum even if short-term overbought signals (such as an RSI of 74.7) appear. Past successful comparable cases include instances involving MRNA stocks that share the keyword 'Moderna', such as 2026-09-13 (return: 128.7%, news: Moderna’s stock doubles on promising cancer-vaccine results), 2026-08-20 (return: 125.8%, news: Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial), and 2026-08-28 (return: 113.7%, news: Moderna, Merck rise after late-stage trial win for mRNA cancer therapy), which exhibit a trend similar to the current situation in terms of positive news and clinical achievement momentum related to Moderna's cancer vaccines.

Moderna's share price surged after its cancer vaccine candidate, combined with the immuno-oncology drug Keytruda, produced positive clinical trial results. Take profit when the target price of $65.53 is reached, and cut losses if the stock falls below the stop-loss price of $52.66. Entry was considered based on a strong news catalyst of favorable cancer vaccine clinical trial results and a recent 7-day upward price momentum of +6.4%. The RSI(14) is at 67.2, approaching the overbought territory, the moving averages are not in a bullish alignment, and the trading volume is at 0.80 times the 20-day average. At the time of the prediction, a conservative target return of 4.5% was set based on a strong news catalyst—positive clinical trial results for a cancer vaccine—and a recent 7-day volatility upward trend of +6.4%. However, the actual result recorded an explosive surge of 128.7%, resulting in an OVERHIT rating. Although the further upside potential was evaluated somewhat conservatively due to entering the overbought zone with an RSI of 67.2 and a low trading volume ratio of 0.80x at the time, it was confirmed that the explosive impact of Moderna's pipeline expectations on the actual stock price, akin to past similar cases, was not fully reflected. Through this trade, we confirmed that positive news regarding innovative new drugs in the large-cap pharma/biotech theme can exert disruptive force far exceeding market expectations, despite technical indicators showing short-term overheating (such as an RSI of 67.2) or somewhat sluggish trading volume (0.80x). When encountering similar clinical success news or major pipeline-related catalysts in the future, we will adjust our strategy to avoid being constrained solely by temporary overheating in technical indicators and instead trust the ripple effect of the positive news and the explosive upward patterns demonstrated by past similar success cases, leaving our profit-taking targets more flexibly open. This is in line with past cases where the stock rose on favorable news related to similar cancer vaccine clinical trials by MRNA (September 13, 2026: 128.7% return, August 20, 2026: 125.8% return, August 28, 2026: 113.7% return).

Moderna's stock price surged more than 100% on news of the clinical success of its melanoma vaccine. Depending on the outcome, take profit at $65.53 or respond with a stop-loss at $52.66 — the take-profit target of $65.53 and the stop-loss price of $52.66 for this trade are values produced by REPORTING. Entry was considered based on the strong positive catalyst of clinical success for the melanoma vaccine and the recent 7-day price change trend of +6.4%. Technical indicators at the time of entry were RSI(14) of 67.2, moving averages not in bullish alignment, trading volume at 0.80x the 20-day average, and a 7-day change of +6.4%. The RSI of 67.2 is a level approaching the overbought zone, and trading volume is somewhat low at 0.80x the 20-day average. Entered the position with a projected return of 4.5% in view, but the actual outcome recorded a massive surge of 131.2%, earning an OVERHIT verdict. The entry decision was driven by the powerful catalyst of a successful melanoma vaccine clinical trial and a volatility rate of +6.4%; however, the technical indicators at the time—RSI of 67.2, trading volume at 0.80x the 20-day average, and non-aligned moving averages—made it difficult to fully gauge the magnitude of such explosive upward momentum. The market had formed a far greater wave of buying pressure that went well beyond a simple reaction to the positive news. Through this trade, I was reminded that when a major biotech catalyst breaks out, even if technical indicators (such as an RSI of 67.2 or a low volume ratio) appear somewhat conservative, one must be careful not to underestimate the explosive impact that a fundamental catalyst like a strong clinical success can deliver. Going forward, when trading similar bio-sector events, I should avoid being bound solely by the resistance levels or conservative readings of initial indicators, and instead establish a flexible profit-taking strategy that leaves room for the catalyst's ripple effects and the theme's potential transition to S-Class.